First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - Concepedia

Concepedia

Publication | Open Access

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

DOI Full Paper Access

250

Citations

23

References

2021

Year

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant,

EClinicalMedicine

Abstract

This trial was funded by 3-V Biosciences, Inc. (now known as Sagimet Biosciences Inc.).

References

	Year	Citations

Page 1